Full Name
Wee Joo Chng
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Wee Joo Chng
Chng, W.-J.
 
 
 
Email
mdccwj@nus.edu.sg
 
 

Publications

Refined By:
Date Issued:  [2000 TO 2021]
Type:  Review
Department:  DEAN'S OFFICE (MEDICINE)
Policy:  Open

Results 1-20 of 27 (Search time: 0.014 seconds).

Issue DateTitleAuthor(s)
123-Feb-2021Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer ProgressionVinaiphat, Arada; Low, Jee Keem; Yeoh, Kheng Wei ; Chng, Wee Joo ; Sze, Siu Kwan
229-Apr-2021CAR T-cell therapy in multiple myeloma: more room for improvementTeoh, Phaik Ju ; Chng, Wee Joo 
31-Nov-2019Comprehensive Analysis of ERK1/2 Substrates for Potential Combination ImmunotherapiesYang, Lei ; Zheng, Liangzhen; Chng, Wee Joo ; Ding, Jeak Ling 
42020Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaDimopoulos, M.A.; Jakubowiak, A.J.; McCarthy, P.L.; Orlowski, R.Z.; Attal, M.; Bladé, J.; Goldschmidt, H.; Weisel, K.C.; Ramasamy, K.; Zweegman, S.; Spencer, A.; Huang, J.S.Y.; Lu, J.; Sunami, K.; Iida, S.; Chng, W.-J. ; Holstein, S.A.; Rocci, A.; Skacel, T.; Labotka, R.; Palumbo, A.; Anderson, K.C.
52019EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implicationsLi, B. ; Chng, W.-J. 
62020Immunoglobulin m paraproteinaemiasGirard, L.-P.; Soekojo, C.Y.; Ooi, M.; Poon, L.M.; Chng, W.-J. ; de Mel, S.
71-Mar-2020Immunotherapy in Multiple MyelomaSoekojo, Cinnie Yentia; Ooi, Melissa ; de Mel, Sanjay; Chng, Wee Joo 
82014Implications of heterogeneity in multiple myelomaDe Mel S.; Lim S.H.; Tung M.L.; Chng W.-J. 
91-Oct-2021Janus Kinase Signaling: Oncogenic Criminal of Lymphoid CancersLi, Boheng; Wan, Qin; Li, Zhubo; Chng, Wee-Joo 
102014MicroRNA: Important player in the pathobiology of multiple myelomaBi C.; Chng W.J. 
112011miRNA deregulation in multiple myelomaBi C.L.; Chng W.J. 
122014MMSET: Role and therapeutic opportunities in multiple myelomaXie Z.; Chng W.J. 
132-Apr-2019Molecular pathogenic pathways in extranodal NK/T cell lymphomade Mel, Sanjay; Hue, Susan Swee-Shan; Jeyasekharan, Anand D ; Chng, Wee-Joo ; Ng, Siok-Bian 
142014P53 abnormalities and potential therapeutic targeting in multiple myelomaTeoh P.J.; Chng W.J. 
152018Potential clinical application of genomics in multiple myelomaSoekojo, C.Y; de Mel, S; Ooi, M ; Yan, B; Chng, W.J 
162017Recent advances in acute promyelocytic leukaemiaNg, C.-H ; Chng, W.-J 
171-Aug-2020Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in SingaporeTan, David Shao-Peng; Tan, Daniel Shao-Weng; Tan, Iain Bee Huat ; Yan, Benedict; Choo, Su Pin ; Chng, Wee Joo ; Hwang, William Ying Khee
1814-Sep-2018RESISTANCE TO FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA: MOLECULAR MECHANISMS AND RESENSITIZING STRATEGIESZhou, J ; CHNG WEE JOO 
191-May-2019STAT3: A Promising Therapeutic Target in Multiple MyelomaChong, Phyllis SY ; Chng, Wee-Joo ; de Mel, Sanjay
202019Super-enhancers: Critical roles and therapeutic targets in hematologic malignanciesJia, Y.; Chng, W.-J. ; Zhou, J.